Pharming Group NV Quote - PHAR

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

7.65

Bid

3.84

Ask

7.93

Volume

9,940

7.64 Day's Range 7.95

0.00 52 Week Range 0.00

Market Cap

513.371M

Previous Close

7.53

Open

7.85

Last Trade

7.77

Last Trade Time

Financial Volume

US$ 77,099

VWAP

7.7565

Average Volume (3m)

Shares Outstanding

67,107,324

Dividend Yield

PE Ratio

-4.64

Earnings Per Share (EPS)

-0.16

Revenue

245.32M

Net Profit

-10.55M

Pharming Group is engaged in the development of products for the treatment of unmet medical needs. Pharming Group is engaged in the development of products for the treatment of unmet medical needs.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Diversified

Website

www.pharming.com

Headquarters

Leiden, South Holland, Nld

Founded

1988

Pharming Group NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PHAR. The last closing price for Pharming Group NV was US$7.53. Over the last year, Pharming Group NV shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Pharming Group NV currently has 67,107,324 shares outstanding. The market capitalization of Pharming Group NV is US$505.32 million. Pharming Group NV has a price to earnings ratio (PE ratio) of -4.64.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ZENAZenaTech Inc	US$ 6.42 (258.66%)	116.31M
QMCOQuantum Corporation	US$ 21.67 (137.35%)	30.84M
SMTKSmartKem Inc	US$ 5.50 (71.88%)	3.16M
INVZWInnoviz Technologies Ltd	US$ 0.085 (70.00%)	152.17k
RGTIRigetti Computing Inc	US$ 2.75 (58.05%)	270.55M
SAVACassava Sciences Inc	US$ 4.295 (-83.78%)	92.51M
ONCTOncternal Therapeutics Inc	US$ 0.73 (-35.96%)	775.67k
CRKNCrown Electrokinetics Corporation	US$ 0.4246 (-35.43%)	12.69M
HTLMHomesToLife Ltd	US$ 2.60 (-34.59%)	213.36k
AMPGAmplitech Group Inc	US$ 0.92 (-25.81%)	688.86k
NVDANVIDIA Corporation	US$ 136.02 (-4.18%)	340.12M
ELABElevai Labs Inc	US$ 0.0157 (-21.89%)	323.5M
RGTIRigetti Computing Inc	US$ 2.75 (58.05%)	270.55M
SMCISuper Micro Computer Inc	US$ 38.42 (15.90%)	168.62M
CTXRCitius Pharmaceuticals Inc	US$ 0.1337 (-0.07%)	143.5M

stockinspector 4 minutes ago

That is just market makers getting out of the way. Mr Dastardley

WDLF

tradeherpete 5 minutes ago

I believe most don't understand the power of human intention. It's communicated through the gut, the brain, your actions, your hopes and your dreams.

If someone activates that in someone else, that person is capable things not thought possible. We have beautiful brains but they can'

AVXL

XMaster2023 6 minutes ago

I guess what you say does make a difference.

Where do you think I copied this from?

“323. Indeed, on days when the price rose after a Spoofing Episode, data demonstrates that this price increase would have occurred even absent Defendant’s spoofing. Defendants’ manipulat

NWBO

FACT-MASTER 6 minutes ago

Thank you very much for your input.

I like ESPR as well and concur that VRNA is a good comparable.
I think ESPR could move quickly ( 2025) as you mentioned it is a BIG space.

https://www.esperion.com/news-releases/news-release-details/us-fda-approves-broad-new-l

ESPR VRNA

Rkramden 7 minutes ago

Fwiw

https://search.app?link=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMOVELLA-HOLDINGS-INC-150653517%2Fnews%2FMovella-Late-Filing-Notice-Form-NT-10-Q-48455209%2F&utm_campaign=aga&utm_source=agsadl1%2Cagsadl4%2Csh%2Fx%2Fgs%2Fm2%2F4

MVLA

Bostonsesco 7 minutes ago

$300 Plus a share if dividends aren't lucrative enough to retire

FNMA

Legend431 8 minutes ago

You have been around pumping an otc stock for some time on a daily basis. So that puts you on the same level as Ex!!

NWBO

Legend431 9 minutes ago

That is a lie. It is a not a cure. They defeated noting

NWBO

blackhawks 9 minutes ago

This is up to date.....and I found it in the AI sources.

Bias scores for articles and shows are on a scale of -42 to +42, with higher negative scores being more left, higher positive scores being more right, and scores closer to zero being minimally biased, equally balanced, or exhibi

dinogreeves 10 minutes ago

I sold, you can choose to believe me or you don't, I don't care and I am not disgruntled either, couple thousand loss here, doesn't break my bank, the only reason PB is here, just like with his other dud, EMG*E, he has been on every OTC with massive dilution after dilution. It should make you wonde

AFFU

cadillacdave 10 minutes ago

I still believe he will cobble together some sort of deal. The question is - how will he be able to monetize it, to make it worthwhile for shareholders.

WDDD

bas2020 10 minutes ago

You're exactly right! It's your bosses' ongoing manipulation behind a curtain of daily FUD... attacking the next SoC in cancer therapy.
Somethings been wrong for a long time.

NWBO

Think1st 11 minutes ago

Co fault for dumping billions of shares on shareholders from drop from 0.02 range to 0.0005
So yes it will take time to absorb the shares

AUNXF

hedge_fun 11 minutes ago

I bet you’ll enjoy this. It’s amazing how…..

shallow treasure wrecks have booty scattered, but Juno is “allegedly” the largest find in history, yet the treasure is “allegedly” all under worm poop.

[yt]euHThh5-ric[/yt]

SFRX

farml1234 12 minutes ago

I think several posters on this board are very nervous

Me i on cloud 10

jmho

ERHE

samson8 12 minutes ago

Nope. They actually have a warning on the wall in the video they posted on Twitter that says their stem cell treatments are not FDA approved.Is this clinic even legal? When's the first lawsuit?

https://x.com/ADIA_Nutrition/status/1861054346240110847?t=ruhw4KaFOxCWaWSndJ0wVQ&s=19

ADIA

Jetmek_03052 13 minutes ago

Not even a SINGLE SHARE naked shorted!

If there were any, we’d have seen covering long before now!

The NSS fairy tale was a ridiculous story years ago and CONTINUES to be a ridiculous story TODAY!

DBMM

HoldEm777 13 minutes ago

Which ones Bill? Which “bushers ” are you exactly referring too? Don’t be shy… Chee Chee Chee $RDAR

RDAR

XMaster2023 14 minutes ago

73 coauthors of the journal article indicate management did not screw up. Who to believe, 73 professionals (mostly PHD’s) or a bloke without a degree or even basic common sense on how to pick a job not criticizing the next generation of cancer treatment.

NWBO

Alpha14 15 minutes ago

When

RNVA

Shev11 15 minutes ago

Feels like this wants to make a move. Give us something good frank.

IMTL

dinogreeves 15 minutes ago

https://finance.yahoo.com/video/chips-act-grants-could-look-214313138.html

SMCI

	Real-time Prices	Level 2
Dow Jones Indices
Toronto Stock Exchange
Toronto Stock Exchange Venture Exchange
OTCBB
New York Stock Exchange
NASDAQ
American Stock Exchange
OTCMarkets
Canadian Securities Exchange
OPRA
OPRA Indices
Forex

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Pharming Group NV (PHAR)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

About Pharming Group NV

Ask ADVFN Intelligence (AI)

PHAR Latest News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Pharming Group to participate in September investor conferences

Pharming Group to convene Extraordinary General Meeting of Shareholders

Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

BLACK FRIDAY

Save up to 60%* for North American Extreme

1 year 40%, 2 years 40% and *3 years 60%

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Pharming Group NV (PHAR) Share Price

Pharming Group NV (PHAR)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

About Pharming Group NV

Ask ADVFN Intelligence (AI)

PHAR Latest News

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

BLACK FRIDAY

Save up to 60%* for Canadian Securities Exchange (CSE) Level 1 and 2

1 year 40%, 2 years 40% and *3 years 60%

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR